Proteolysis Inhibitors Fail to Halt Metastasis
By Biotechdaily staff writers
Posted on 04 Feb 2003
Researchers have found that some types of cancer cells revert to a primitive amoeboid form of movement when treated with enzyme inhibitors intended to prevent the normal proteolysis-based movement of the cells during metastasis. The finding was reported in the January 20, 2003, issue of the Journal of Cell Biology.Posted on 04 Feb 2003
Investigators from the University of Wuerzburg (Germany) treated fibrosarcoma and carcinoma cells with a series of inhibitors to prevent the proteolytic activity of MT1–matrix metalloproteinase (MMP), which normally allows the cancer cells to burrow through the extracellular matrix (ECM) and spread from the site of the original tumor. They found that the treated cancer cells changed shape, became rounded, and were able to squeeze through already existing gaps in the ECM by using an amoeba-like movement.
The authors concluded that to be successful in preventing metastasis, drug treatments against proteolysis-dependent movement must be supplemented with agents capable of stopping the amoeboid movement.
Related Links:
University of Wuerzburg
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
.jpg)
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
POC Immunoassay Analyzer
Procise DX
New
Multi-Chamber Washer-Disinfector
WD 390
